The impact of fetal fibronectin testing for women with symptoms of preterm labour in routine clinical practice within a New Zealand population

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 46, Issue 5, 2006, Pages 440-445

  Groom, Katie M ^a,b   Liu, Emily ^a   Allenby, Keith ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

^b NONE   (New Zealand)

Author keywords

Fetal fibronectin; Preterm birth; Preterm labour

Indexed keywords

BETAMETHASONE; CORTICOSTEROID DERIVATIVE; FIBRONECTIN; NIFEDIPINE;

ADOLESCENT; ADULT; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DATA ANALYSIS; DIAGNOSTIC ACCURACY; DRUG COST; FEMALE; FETUS MONITORING; GESTATIONAL AGE; HEALTH CARE COST; HEALTH CARE DELIVERY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; NEW ZEALAND; OUTCOMES RESEARCH; POPULATION RESEARCH; PREDICTION; PREMATURE LABOR; PRENATAL CARE; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SLOW DRUG RELEASE; SYMPTOMATOLOGY; TOCOLYSIS; TREATMENT PLANNING;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; FEMALE; FIBRONECTINS; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; NEW ZEALAND; OBSTETRIC LABOR, PREMATURE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREMATURE BIRTH; PRENATAL CARE; RETROSPECTIVE STUDIES; RISK FACTORS; TOCOLYSIS; UNNECESSARY PROCEDURES;

EID: 33748201087     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2006.00631.x     Document Type: Review

References (22)

1. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2000: CD000065.
2. Chien LY, Whyte R., AziZ. K, Thiessen P, Matthew D, Lee SK. Improved outcome of preterm infants when delivered in tertiary care centers. Obstet Gynecol 2001; 98: 247-252.
3. Darlow BA, Cust AE, Donaghue DA. Improved outcomes for very low birthweight infants: Evidence from New Zealand national population based data. Arch Dis Child Fetal Neonatal Ed 2003; 88: F23-F28.
4. Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: A systematic review. Obstet Gynecol 1999; 94: 869-877.
5. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: Fetal fibronectin testing and spontaneous preterm birth. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996; 87 (5 Part 1): 643-648.
6. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: Systematic review. BMJ 2002; 325: 301.
7. Leitich H, Egarter C, Kaider A, Hohlagschwandtner M, Berghammer P, Husslein P. Cervicovaginal fetal fibronectin as a marker for preterm delivery: A meta-analysis. Am J Obstet Gynecol 1999; 180: 1169-1176.
8. Peaceman AM, Andrews WW, Thorp JM et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: A multicenter trial. Am J Obstet Gynecol 1997; 177: 13-18.
9. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, Lowensohn R. et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995; 173: 141-145.
10. Lowe MP, Zimmerman B, Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center. Am J Obstet Gynecol 2004; 190: 358-362.
11. Grobman WA, Welshman EE, Calhoun EA. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2004; 191: 235-240.
12. Plaut MM, Smith W, Kennedy K. Fetal fibronectin: The impact of a rapid test on the treatment of women with preterm labour symptoms. Am J Obstet Gynecol 2003; 188: 1588-1593.
13. Joffe GM, Jacques D, Bemis-Heys R., Burton R., Skram B, Shelburne P. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999; 180 (3 Part 1): 581-586.
14. Abenhaim HA, Morin L, Benjamin A. Does availability of fetal fibronectin testing in the management of threatened preterm labour affect the utilization of hospital resources. J Obstet Gynaecol Can 2005; 27: 689-694.
15. Parry E, Singh TG, Dow D, Noovao F. Improved management in threatened preterm labour with rapid fetal fibronectin testing. Aust N Z J Obstet Gynaecol 2006; 46: 240-241.
16. Foxman EF, Jarolim P. Use of the fetal fibronectin test in decisions to admit to hospital for preterm labor. Clin Chem 2004; 50: 663-665.
17. Giles W, Bisits A, Knox M, Madsen G, Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal-fetal medicine unit and cost savings. Am J Obstet Gynecol 2000; 182: 439-442.
18. Alonso LA, Mendez. JA, Solis GJ, Gutierrez. FA, Cueto LD. Economic impact on the management of preterm labour based on the result of fetal fibronectin. Ginecol Obstet Mex 2004; 72: 385-393.
19. Sullivan A, Hueppchen NA, Satin AJ. Cost effectiveness of bedside fetal fibronectin testing varies according to treatment algorithm. J Matern Fetal Med 2001; 10: 380-384.
20. National Health and Medical Research Council. When Does Quality Assurance in Health Care Require Independent Medical Review? 2003. [Accessed 21 April 2006.]Available from http://www.nhmrc.gov.au/ publications/_files/e46.pdf
21. New Zealand Operational Standard for Ethics Committees. New Zealand Operational Standard for Ethics Committees. Matters Requiring Ethical Review. [Accessed 21 April 2006.]Available from http://www.moh.govt.nz/moh.nsf/49ba80c00757b8804c256673001d47d0/ ffc06a2c2009deeecc256b9400787b61/$FILE/ OperationalStandard_final.pdf
22. Musaad SM, Melson CL, Boswell DR. Assessment of the impact of introducing fetal fibronectin assay in the management of preterm labour at Middlemore Hospital, New Zealand. Pathology 2005; 37: 226-230.